Literature DB >> 11669605

LMP1 structure and signal transduction.

A G Eliopoulos1, L S Young.   

Abstract

The oncogenic Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) has structural features and functions reminiscent of a constitutively active TNF family receptor. LMP1 aggregates at the plasma membrane and initiates the activation of signalling pathways, such as NF- kappa B, the mitogen-activated protein kinases JNK and p38, the small GTPase Cdc42 and the JAK/STAT cascade. The constitutive engagement of these signals and the characteristic molecular interactions that regulate them provide the basis for the molecular explanation of the transforming properties of this key EBV protein. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11669605     DOI: 10.1006/scbi.2001.0410

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  85 in total

1.  TRAF1 is a critical regulator of JNK signaling by the TRAF-binding domain of the Epstein-Barr virus-encoded latent infection membrane protein 1 but not CD40.

Authors:  Aristides G Eliopoulos; Elyse R Waites; Sarah M S Blake; Clare Davies; Paul Murray; Lawrence S Young
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Epstein-Barr virus latent membrane protein LMP-2A is sufficient for transactivation of the human endogenous retrovirus HERV-K18 superantigen.

Authors:  Natalie Sutkowski; Gang Chen; German Calderon; Brigitte T Huber
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

3.  The Epstein-Barr virus EBNA-LP protein preferentially coactivates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter.

Authors:  Rongsheng Peng; Stephanie C Moses; Jie Tan; Elisabeth Kremmer; Paul D Ling
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Interferon regulatory factor 5 represses expression of the Epstein-Barr virus oncoprotein LMP1: braking of the IRF7/LMP1 regulatory circuit.

Authors:  Shunbin Ning; Leslie E Huye; Joseph S Pagano
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 5.  IRF7: activation, regulation, modification and function.

Authors:  S Ning; J S Pagano; G N Barber
Journal:  Genes Immun       Date:  2011-04-14       Impact factor: 2.676

6.  Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen modulates K1 expression through its cis-acting elements within the terminal repeats.

Authors:  Subhash C Verma; Ke Lan; Tathagata Choudhuri; Erle S Robertson
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

7.  Opposing roles for TRAF1 in the alternative versus classical NF-κB pathway in T cells.

Authors:  Ann J McPherson; Laura M Snell; Tak W Mak; Tania H Watts
Journal:  J Biol Chem       Date:  2012-05-08       Impact factor: 5.157

8.  Targeting EBV-LMP1 DNAzyme enhances radiosensitivity of nasopharyngeal carcinoma cells by inhibiting telomerase activity.

Authors:  Lifang Yang; Zhijie Xu; Liyu Liu; Xiangjian Luo; Jingchen Lu; Lunquan Sun; Ya Cao
Journal:  Cancer Biol Ther       Date:  2013-10-21       Impact factor: 4.742

9.  Roles of the TRAF2/3 binding site in differential B cell signaling by CD40 and its viral oncogenic mimic, LMP1.

Authors:  John P Graham; Carissa R Moore; Gail A Bishop
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

10.  Synergism of BARF1 with Ras induces malignant transformation in primary primate epithelial cells and human nasopharyngeal epithelial cells.

Authors:  Richeng Jiang; Giulia Cabras; Wang Sheng; Yixin Zeng; Tadamasa Ooka
Journal:  Neoplasia       Date:  2009-09       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.